NUVATION BIO INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.935 USD | +2.98% |
|
+4.64% | +94.04% |
| Sales 2024 * | - | Sales 2025 * | 660K 903K | Capitalization | 704M 964M |
|---|---|---|---|---|---|
| Net income 2024 * | -78M -107M | Net income 2025 * | -137M -187M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1,067 x |
| P/E ratio 2024 * |
-10.2
x | P/E ratio 2025 * |
-6.69
x | Employees | 159 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.5% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +3.33% | ||
| 1 week | +4.64% | ||
| Current month | -5.48% | ||
| 1 month | -13.06% | ||
| 3 months | +25.75% | ||
| 6 months | +120.30% | ||
| Current year | +94.04% |
1 week
2.73
3.03
1 month
2.573.55
Current year
1.434.16
1 year
0.954.16
3 years
0.9511.81
5 years
0.9515.23
10 years
0.9515.23
| Managers | Title | Age | Since |
|---|---|---|---|
David Hung
FOU | Founder | 67 | 18-03-19 |
Moses Makunje
DFI | Director of Finance/CFO | 46 | 20-06-30 |
Dong Fang Liu
CTO | Chief Tech/Sci/R&D Officer | 54 | 22-07-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Hung
FOU | Founder | 67 | 18-03-19 |
Kim Blickenstaff
BRD | Director/Board Member | 71 | 19-07-31 |
Kathryn Falberg
BRD | Director/Board Member | 63 | 20-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.02% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-12 | 2.93 | +2.81% | 293 504 |
| 24-06-11 | 2.85 | -1.72% | 1,318,799 |
| 24-06-10 | 2.9 | +4.69% | 1,672,038 |
| 24-06-07 | 2.77 | -4.81% | 1,572,990 |
| 24-06-06 | 2.91 | +3.93% | 2,182,544 |
Delayed Quote Nyse, June 12, 2024 at 12:51 pm
More quotes
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Calendar
2024-07-10
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.85
USD
Average target price
6.6
USD
Spread / Average Target
+131.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +94.04% | 704M | |
| +48.78% | 56.87B | |
| +37.15% | 39.72B | |
| -6.08% | 39.27B | |
| -6.90% | 28.73B | |
| +13.38% | 26.21B | |
| -16.02% | 19.79B | |
| +32.41% | 12.28B | |
| +27.55% | 12.23B | |
| +0.62% | 12.12B |
- Stock Market
- Equities
- NUVB Stock
